A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs BMS 986012 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2017 Planned End Date changed from 1 Oct 2018 to 1 Sep 2018.
- 03 Mar 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Sep 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History